RxDoctor Payments Data

Alexis Lindsey, PA

Physician Assistant · Imperial, MONPI 1396352860

Payments from drug & device makers

$6,324in general payments, 2019–2025

Across 347 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$569
  • Novo Nordisk$562
  • Lilly USA, LLC$345
  • Corcept Therapeutics$203
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$192
  • plus $984 from 16 others

What the payments were for

  • Food & beverage$6,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,324 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$36,176
Medicare patients
139
Services billed
673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$46,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$31,381
JardianceEmpagliflozin24$28,710
MounjaroTirzepatide21$21,996
FarxigaDapagliflozin Propanediol19$20,898
TrulicityDulaglutide13$20,149
EliquisApixaban15$12,300
Praluent PenAlirocumab12$5,917
Albuterol Sulfate HfaAlbuterol Sulfate59$1,330
Levothyroxine Sodium63$924
Bupropion XlBupropion Hcl31$767
Diclofenac Sodium21$664
Atorvastatin Calcium56$527
Duloxetine Hcl34$509
Pantoprazole Sodium25$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$562$46,72929 claims
Lilly USA, LLCMounjaro, Trulicity$345$42,14534 claims
GSKTrelegy Ellipta$169$31,38126 claims
Boehringer IngelheimJardiance$19$28,71024 claims
AstraZenecaFarxiga$569$20,89819 claims
PfizerEliquis$165$12,30015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Imperial

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →